Regeneron Pharmaceuticals (REGN) Competitors

Amgen (NASDAQ:AMGN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability, community ranking and earnings.

Does the media prefer AMGN or REGN?

In the previous week, Amgen had 30 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 76 mentions for Amgen and 46 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.05 beat Amgen's score of 0.97 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	47 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	11 Negative mention(s)	1 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	31 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	8 Negative mention(s)	1 Very Negative mention(s)	Positive

Which has more volatility and risk, AMGN or REGN?

Amgen has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.

Which has higher earnings & valuation, AMGN or REGN?

Regeneron Pharmaceuticals has lower revenue, but higher earnings than Amgen. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$33.42B	4.73	$4.09B	$7.55	38.93
Regeneron Pharmaceuticals	$14.20B	4.40	$4.41B	$38.28	14.92

Is AMGN or REGN a better dividend stock?

Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Regeneron Pharmaceuticals pays an annual dividend of $0.88 per share and has a dividend yield of 0.2%. Amgen pays out 126.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Regeneron Pharmaceuticals pays out 2.3% of its earnings in the form of a dividend. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Is AMGN or REGN more profitable?

Regeneron Pharmaceuticals has a net margin of 31.07% compared to Amgen's net margin of 12.24%. Amgen's return on equity of 176.32% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	12.24%	176.32%	11.71%
Regeneron Pharmaceuticals	31.07%	16.32%	12.76%

Do institutionals and insiders hold more shares of AMGN or REGN?

76.5% of Amgen shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.7% of Amgen shares are held by company insiders. Comparatively, 7.5% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the MarketBeat Community favor AMGN or REGN?

Amgen received 3 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 71.83% of users gave Amgen an outperform vote while only 66.95% of users gave Regeneron Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Amgen	Outperform Votes 1553 71.83%	Underperform Votes 609 28.17%
Regeneron Pharmaceuticals	Outperform Votes 1550 66.95%	Underperform Votes 765 33.05%

Do analysts recommend AMGN or REGN?

Amgen presently has a consensus target price of $314.91, indicating a potential upside of 7.14%. Regeneron Pharmaceuticals has a consensus target price of $964.88, indicating a potential upside of 68.96%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	9 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.48
Regeneron Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.77

Summary

Regeneron Pharmaceuticals beats Amgen on 12 of the 22 factors compared between the two stocks.